First, absolute incidence: in the pooled STEP 1 to 3 obesity trials of semaglutide 2.4 mg (the Wegovy weight-management dose), constipation affected 24.2% of patients versus 11.1% on placebo , alongside nausea (43.9%), diarrhoea (29.7%), and vomiting (24.5%)
Sources Find out If Your Insurance Covers Ozempic, NovoCare Savings | Coverage | Support, accessed January 2, 2024, Diabetes Savings Offer Program: Novo Nordisk Savings Offer, NovoCare Savings | Coverage | Support, accessed January 2, 2024, Medicare Drug Coverage (Part D). Medicare
2023, 1293926, besity Medicine Association
You've tried the workouts
Before intake: Public pages describe personalized GLP-1 care at a high level, but no eligibility determinations or clinical judgments occur at this stage, and Measured controls only information display